Skip to main content

Table 2 Patients characteristics according to neutrophil-to-lymphocyte ratio /platelet-to-lymphocyte ratio

From: Combination versus single-agent as palliative chemotherapy for gastric cancer

Characteristics

Total N (%)

NLR

P value

PLR

P value

Low

Higha

Low

Highb

Gender

   

0.116

  

0.562

 Male

478 (69.6)

229 (66.8)

249 (72.4)

 

243 (70.6)

235 (68.5)

 

 Female

209 (30.4)

114 (33.2)

95 (27.6)

 

101 (29.4)

108 (31.5)

 

Age (years)

   

0.375

  

0.235

  < 70

562 (81.8)

276 (80.5)

286 (83.1)

 

275 (79.9)

287 (83.7)

 

  ≥ 70

125 (18.2)

67 (19.5)

58 (16.9)

 

69 (20.1)

56 (16.3)

 

PS (ECOG)

   

0.020

  

0.333

 0, 1

611 (88.9)

315 (91.8)

296 (86.0)

 

310 (90.1)

301 (87.8)

 

 2, 3

76 (11.1) c

28 (8.2)

48 (14.0)

 

34 (9.9)

42 (12.2)

 

Disease status

   

< 0.0001

  

< 0.0001

 Primary metastatic

383 (55.7)

155 (45.2)

228 (66.3)

 

166 (48.3)

217 (63.3)

 

 Recurrent

304 (44.3)

188 (54.8)

116 (33.7)

 

178 (51.7)

126 (36.7)

 

Tumor differentiation

   

0.166

  

0.777

 Well, moderate

167 (24.3)

92 (26.8)

75 (21.8)

 

88 (25.6)

79 (23.0)

 

 Poor

186 (27.1)

83 (24.2)

103 (29.9)

 

95 (27.6)

91 (26.5)

 

 Signet ring cell

171 (24.9)

81 (23.6)

90 (26.2)

 

81 (23.5)

90 (26.2)

 

 Combined, others

163 (23.7)

87 (25.4)

76 (22.1)

 

80 (23.3)

83 (24.2)

 

Peritoneal metastasis

   

0.039

  

< 0.0001

 No

373 (54.3)

200 (58.3)

173 (50.3)

 

220 (64.0)

153 (44.6)

 

 Yes

314 (45.7)

143 (41.7)

171(49.7)

 

124 (36.0)

190 (55.4)

 

Liver metastasis

   

1.000

  

0.004

 No

535 (77.9)

267 (77.8)

268 (77.9)

 

252 (73.3)

283 (82.5)

 

 Yes

152 (22.1)

76 (22.2)

76 (22.1)

 

92 (26.7)

60 (17.5)

 

1st line CTx

   

0.286

  

0.929

 Single-agent

166 (24.2)

89 (25.9)

77 (22.4)

 

84 (24.4)

82 (23.9)

 

 Combination

521 (75.8)

254 (74.1)

267 (77.6)

 

260 (75.6)

261 (76.1)

 

Palliative surgical resection

   

< 0.0001

  

0.775

 No

549 (79.9)

250 (72.9)

299 (86.9)

 

273 (79.4)

276 (80.5)

 

 Yes

138 (20.1)

93 (27.1)

45 (13.1)

 

71 (20.6)

67 (19.5)

 

PLR

   

< 0.0001

  

 Low

344 (50.1)

248 (72.3)

96 (27.9)

 

 

 High

343 (49.9)

95 (27.7)

248 (72.1)

 

 
  1. a > median (2.67), b > median (167.21). c PS 3: 2 patients
  2. NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, N number, PS performance status, ECOG Eastern Cooperative Oncology Group, CTx Chemotherapy